BioSpace News Archive

JDRF joined thousands within the diabetes community at the American Diabetes Association’s 83rd Scientific Sessions, where hundreds of experts presented significant advancements in diabetes research that may prove to be pivotal in improving lives and finding cures for T1D.

Imunon, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 5,000 shares of common stock and restricted stock grants totaling 1,000 shares of common stock as a material inducement to the employment to one individual hired by Imunon during the second quarter of 2023.

Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data from retatrutide, Lilly’s investigational molecule being studied for the treatment of obesity.

Coherus BioSciences, Inc., announced that effective June 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 48,000 shares of the common stock of the Company to six newly hired employees with a per share exercise price of $3.84, the closing trading price on the grant date.

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715), “Sun Pharma” is pleased to announce Health Canada’s approval of PRABSORICA LD® (isotretinoin capsules).

Therapeutic Solutions International (TSOI) announced today filing with the FDA for Orphan Drug Designation for its JadiCell Adult Stem Cell Product for treatment of Acute Respiratory Distress Syndrome (ARDS).

BioTech Medics, Inc. is pleased to announce that the firm has made significant steps to diversify BMCS into a new dynamic and productive business.

Genesys Spine today announced the launch of the SIros O™ Oblique SI Fusion system.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from the proof-of-concept Phase 2 open-label UNITY clinical trial for the treatment of pregnant individuals at high risk of early-onset severe (EOS) hemolytic disease of the fetus and newborn (HDFN).

Swedish Orphan Biovitrum AB and CTI BioPharma Corp. announced the completion of the acquisition of CTI by Sobi through its indirect wholly owned subsidiary Cleopatra Acquisition Corp..